(Q41657153)

6 October 2017

title

Moxifloxacin is not anti-inflammatory in experimental pneumococcal pneumonia (English)

1 reference

6 October 2017

1 reference

H C Müller-Redetzky

1

1 reference

6 October 2017

S M Wienhold

2

1 reference

6 October 2017

J Berg

3

1 reference

6 October 2017

A C Hocke

4

1 reference

6 October 2017

S Hippenstiel

5

1 reference

6 October 2017

K Hellwig

6

1 reference

6 October 2017

B Gutbier

7

1 reference

6 October 2017

B Opitz

8

1 reference

6 October 2017

J Neudecker

9

1 reference

6 October 2017

J Rückert

10

1 reference

6 October 2017

A D Gruber

11

1 reference

6 October 2017

O Kershaw

12

1 reference

6 October 2017

K Mayer

13

1 reference

6 October 2017

N Suttorp

14

1 reference

6 October 2017

M Witzenrath

15

1 reference

6 October 2017

language of work or name

English

0 references

publication date

17 November 2014

1 reference

Journal of Antimicrobial Chemotherapy

6 October 2017

published in

1 reference

6 October 2017

volume

70

1 reference

6 October 2017

issue

3

1 reference

6 October 2017

page(s)

830-840

1 reference

Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough.

6 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational management

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Azithromycin attenuates lung inflammation in a mouse model of ventilator-associated pneumonia by multidrug-resistant Acinetobacter baumannii

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Toll-like receptor 2 mediates fatal immunopathology in mice during treatment of secondary pneumococcal pneumonia following influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Impact of macrolide therapy in patients hospitalized with Pseudomonas aeruginosa community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Comparative effectiveness of empiric β-lactam monotherapy and β-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Immunomodulatory activities of fluoroquinolones

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Effect of moxifloxacin on secretion of cytokines by human monocytes stimulated with lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Effect of moxifloxacin on production of proinflammatory cytokines from human peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Anti-inflammatory effects of moxifloxacin and human beta-defensin 2 association in human lung epithelial cell line (A549) stimulated with lipopolysaccharide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-kappaB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Moxifloxacin inhibits cytokine-induced MAP kinase and NF-kappaB activation as well as nitric oxide synthesis in a human respiratory epithelial cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Anti-inflammatory effects of antibacterials on human Bronchial epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Streptococcus pneumoniae-induced regulation of cyclooxygenase-2 in human lung tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Systemic use of the endolysin Cpl-1 rescues mice with fatal pneumococcal pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Perturbation of endothelial junction proteins by Staphylococcus aureus alpha-toxin: inhibition of endothelial gap formation by adrenomedullin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

The Sphingosine-1 Phosphate receptor agonist FTY720 dose dependently affected endothelial integrity in vitro and aggravated ventilator-induced lung injury in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Influenza A viruses target type II pneumocytes in the human lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Recognition of Streptococcus pneumoniae by the innate immune system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Innate immune recognition in infectious and noninfectious diseases of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Pharmacodynamics of moxifloxacin and levofloxacin simulating human serum and lung concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Penetration of ampicillin and sulbactam in the lower airways during respiratory infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Protection from experimental ventilator-induced acute lung injury by IL-1 receptor blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU446

21 January 2018

Identifiers

DOI

10.1093/JAC/DKU446

1 reference

6 October 2017

1 reference